recurrent atrial fibrillation market Market Prospective to be Strong Throughout 2021-2027

Comments · 6 Views

The revolutions in personalized drug development, potential device technologies in the pipeline, increasing incidence of recurrent AFib coupled with deteriorating lifestyles would augment the prevalence of the disease leading to the growth of the Recurrent Atrial Fibrillation market.

The global Recurrent Atrial Fibrillation Market is expected to reach USD 25.93 Billion by 2027, according to a new report by Emergen Research. Factors driving this market include augmenting incidence rate of recurrent atrial fibrillation, new product launches for effective treatment of recurrent events, and improved reimbursement scenarios for recurrent AFib treatment drugs along with technological advancements are expected to become the most common growth factors globally in the coming years. Moreover, healthcare experts from the University of Pennsylvania have estimated that patients admitted to intensive care units for COVID-19 treatment are more likely to suffer from arrhythmia and atrial fibrillation. This would be alarming for cardiac patients and would lead to increased sales of atrial fibrillation associated drugs.

It sheds light on the major companies that contribute significantly to the global sector. The report studies the presence of these companies in major geographical regions and their individual placement in the worldwide business. It helps in projecting the growth of recurrent atrial fibrillation through the years and in predicting its expansion in the forecasted time span. The increase in the demand for the product is boosting the overall production to ensure a smooth functioning demand-supply chain.

Click To get SAMPLE PDF (Including Full TOC, Graphs Charts, Table Figures) @https://www.emergenresearch.com/request-sample/71

Key companies profiled in the report include:

Johnson Johnson, Medtronic Plc, Abbott Laboratories, Microport Scientific Corporation, Atricure Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Siemens AG, Koninklijke Philips N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and GlaxoSmithKline.

The report addresses the following key points:

  • The report estimates the expected market size from 2020-2027
  • The report provides a forecast of market drivers, restraints, and future opportunities for the recurrent atrial fibrillation market
  • The report further analyses the changing recurrent atrial fibrillation market dynamics
  • Regional analysis and segmentation of the market with analysis of the regions and segments expected to dominate the market growth
  • Extensive competitive landscape mapping with profiles of the key competitors
  • In-depth analysis of business strategies and collaborations such as mergers and acquisitions adopted by the key companies
  • Revenue forecast, country scope, application insights, and product insights

For more Information or Any Query Visit: @https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market

Emergen Research have segmented the global Recurrent Atrial Fibrillation Market on the basis of product, application, end-uses, and region:

Product Outlook (Revenue, USD Billion; 2017-2027)

  • Device
  • Surgical Devices
    1. Maze Surgery
    2. Catheter Ablation
    3. Radiofrequency Catheter Ablation
      1. Conventional RF Ablation Catheters
      2. Irrigated-tip RF Ablation Catheters
    4. Cryoablation
    5. Microwave Based Catheter Ablation
    6. Laser Based Catheter Ablation
    7. Navigational Advanced Mapping Accessories
  • Non-Surgical Devices
    1. Electric Cardioversion
    2. EP Ablation Catheters
    3. EP Diagnostic Catheter
    4. Conventional Diagnostic Catheters
      1. Fixed Diagnostic Catheters
      2. Steerable Diagnostic Catheters
    5. Advanced Diagnostic Catheters
    6. Mapping and Recording Systems
    7. Cardiac Monitors or Loop Recorders
    8. Access Devices
    9. Left Atrial Appendage and Closure Devices
    10. Intracardiac Echocardiography (ICE) Systems
  • Drugs
    1. Dabigatran (Pradaxa)
    2. Rivaroxaban (Xarelto)
    3. Apixaban (Eliquis)
    4. Edoxaban (Savaysa)
    5. Warfarin (Coumadin)
    6. Others

Application Outlook (Revenue, USD Billion; 2017-2027)

  • EP Ablation
  • Diagnostic
  • Surgical Cardiac

End Users Outlook (Revenue, USD Billion; 2017-2027)

 

  • Hospitals
  • Cardiac Centers
  • Ambulatory Care Centers

 

 

recurrent atrial fibrillation Market Segmentation by Regions:

  • North America (U.S., Canada)
  • Europe (U.K., Italy, Germany, France, Rest of EU)
  • Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Enquire for customization in Report @:https://www.emergenresearch.com/request-for-customization/71

Thank you for reading our report. Please get in touch with us for further queries about the report and our team will assist you according to your needs.

Explore more Emergen Research Reports

Cybersecurity Mesh Market

https://www.emergenresearch.com/industry-report/cybersecurity-mesh-market

Application Performance Monitoring Market

https://www.emergenresearch.com/industry-report/application-performance-monitoring-market

Fc Fusion Protein Market

https://www.emergenresearch.com/industry-report/fc-fusion-protein-market

Aircraft Refurbishing Market

https://www.emergenresearch.com/industry-report/aircraft-refurbishing-market

Electric Vehicle Testing Inspection And Certification Market

https://www.emergenresearch.com/industry-report/electric-vehicle-testing-inspection-and-certification-market

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

 

 

 

Comments